Revestive (Teduglutide)
teduglutide 5 mg injection [28 vials] (&) inert substance diluent [28 x 0.5 mL syringes], 1 pack · INJECTION · PBS code 11808L
AUTHORITY_REQUIREDWhat it costs
AU$19710.6 PBS-determined price per 28 units
Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.
- • First listed on the PBS: 2019-10-01.
- • Repeats: 0.
- • PBS program: HB.
Eligibility criteria for subsidised access
The following is the government's own wording from the PBS Schedule, shown unchanged.
Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1
Type III Short bowel syndrome with intestinal failure
Initial treatment - balance of supply
Must be treated by a gastroenterologist; or
Must be treated by a specialist within a multidisciplinary intestinal rehabilitation unit; AND
Patient must have previously received PBS-subsidised initial treatment with this drug for this condition; AND
Patient must have received insufficient therapy with this drug under the initial treatment restriction to complete the maximum duration of 12 months of initial treatment; AND
The treatment must provide no more than the balance of up to 12 months of treatment.
Sponsor: Takeda Pharmaceuticals Australia Pty. Ltd. ABN 71 095 610 870
Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.
Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.